Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Update on PET imaging biomarkers in the diagnosis of neuropsychiatric disorders.

Hellwig S, Domschke K.

Curr Opin Neurol. 2019 May 6. doi: 10.1097/WCO.0000000000000705. [Epub ahead of print]

PMID:
31083013
2.

Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder.

Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH.

JAMA Psychiatry. 2017 Aug 1;74(8):833-840. doi: 10.1001/jamapsychiatry.2017.1567.

3.

Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.

Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N.

Int J Mol Sci. 2017 Apr 7;18(4). pii: E785. doi: 10.3390/ijms18040785. Review.

4.

[Functional imaging in mental disorders].

Borbély K.

Orv Hetil. 2004 Feb 8;145(6):277-89. Review. Hungarian.

PMID:
15038321
5.

Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia.

Notter T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, Wang Y, Kassiou M, Vernon AC, Benke D, Pomper MG, Sawa A, Meyer U.

Mol Psychiatry. 2018 Feb;23(2):323-334. doi: 10.1038/mp.2016.248. Epub 2017 Jan 17.

PMID:
28093569
6.

Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein.

van der Doef TF, Doorduin J, van Berckel BNM, Cervenka S.

Clin Transl Imaging. 2015;3(6):449-460. doi: 10.1007/s40336-015-0140-0. Epub 2015 Sep 10. Review.

7.

In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders.

Nikolaus S, Antke C, Müller HW.

Behav Brain Res. 2009 Dec 1;204(1):32-66. doi: 10.1016/j.bbr.2009.06.009. Epub 2009 Jun 10. Review.

PMID:
19523495
8.

Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.

Meyer PT, Frings L, Hellwig S.

Curr Opin Neurol. 2014 Aug;27(4):398-404. doi: 10.1097/WCO.0000000000000107. Review.

PMID:
24978635
9.

Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry.

Notter T, Coughlin JM, Sawa A, Meyer U.

Mol Psychiatry. 2018 Jan;23(1):36-47. doi: 10.1038/mp.2017.232. Epub 2017 Dec 5. Review.

PMID:
29203847
10.

Perfusion magnetic resonance imaging in psychiatry.

Théberge J.

Top Magn Reson Imaging. 2008 Apr;19(2):111-30. doi: 10.1097/RMR.0b013e3181808140. Review.

PMID:
19363433
11.

Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.

Shen LH, Liao MH, Tseng YC.

J Biomed Biotechnol. 2012;2012:259349. doi: 10.1155/2012/259349. Epub 2012 Apr 10. Review.

12.

L-3,4-Dihydroxy-6-[F-18]fluorophenylalanine positron emission tomography demonstrating dopaminergic system abnormality in the brains of obsessive-compulsive disorder patients.

Hsieh HJ, Lue KH, Tsai HC, Lee CC, Chen SY, Kao PF.

Psychiatry Clin Neurosci. 2014 Apr;68(4):292-8. doi: 10.1111/pcn.12139. Epub 2014 Jan 9.

13.

Obsessive-compulsive disorder: boundary issues.

Fineberg NA, Saxena S, Zohar J, Craig KJ.

CNS Spectr. 2007 May;12(5):359-64, 367-375. Review.

PMID:
17514081
14.

Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971.

Zanotti-Fregonara P, Zhang Y, Jenko KJ, Gladding RL, Zoghbi SS, Fujita M, Sbardella G, Castellano S, Taliani S, Martini C, Innis RB, Da Settimo F, Pike VW.

ACS Chem Neurosci. 2014 Oct 15;5(10):963-71. doi: 10.1021/cn500138n. Epub 2014 Aug 25.

15.

The genetic architecture of schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder.

O'Connell KS, McGregor NW, Lochner C, Emsley R, Warnich L.

Mol Cell Neurosci. 2018 Apr;88:300-307. doi: 10.1016/j.mcn.2018.02.010. Epub 2018 Mar 2.

PMID:
29505902
16.

Categorical and dimensional aspects of co-morbidity in obsessive-compulsive disorder (OCD).

Ivarsson T, Melin K, Wallin L.

Eur Child Adolesc Psychiatry. 2008 Feb;17(1):20-31. Epub 2007 Nov 14.

PMID:
18004647
17.

N-(6-[18F]Fluoro-4-phenoxypyridin-3-yl)-N-(2-methoxybenzyl)acetamide.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2013 Mar 26 [updated 2013 Apr 25].

18.

Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity.

Val-Laillet D, Aarts E, Weber B, Ferrari M, Quaresima V, Stoeckel LE, Alonso-Alonso M, Audette M, Malbert CH, Stice E.

Neuroimage Clin. 2015 Mar 24;8:1-31. doi: 10.1016/j.nicl.2015.03.016. eCollection 2015. Review.

19.

The serotonin transporter in psychiatric disorders: insights from PET imaging.

Spies M, Knudsen GM, Lanzenberger R, Kasper S.

Lancet Psychiatry. 2015 Aug;2(8):743-755. doi: 10.1016/S2215-0366(15)00232-1. Review.

PMID:
26249305
20.

Radiopharmaceuticals in neurological and psychiatric disorders.

Valotassiou V, Wozniak G, Sifakis N, Demakopoulos N, Georgoulias P.

Curr Clin Pharmacol. 2008 May;3(2):99-107. Review.

PMID:
18690884

Supplemental Content

Support Center